Asia FX muted despite Fed cut bets; Japanese yen slides after PM Ishiba resigns
Trill AB, a significant shareholder of DiaMedica Therapeutics Inc (NASDAQ:DMAC), reported purchasing shares of common stock between August 13 and August 27. The purchases amounted to 953,620 shares, with prices ranging from $5.8573 to $6.00, totaling approximately $5.96 million. The transaction comes as analysts maintain a strong buy consensus with price targets ranging from $11 to $14, suggesting significant upside potential. According to InvestingPro analysis, the company currently trades near its Fair Value, with a market capitalization of $269.3 million.
The transactions, executed under the transaction code "P," increased Trill AB’s holdings in DiaMedica Therapeutics. Following these transactions, Trill AB now holds 7,764,465 shares. Jan Stahlberg, as board member and sole owner of Trill AB, has sole power to vote and dispose of these shares. The company maintains strong financial health with a current ratio of 7.55 and holds more cash than debt on its balance sheet. For deeper insights into insider trading patterns and comprehensive financial analysis, InvestingPro subscribers can access the detailed Pro Research Report, available for over 1,400 US stocks.
In other recent news, DiaMedica Therapeutics reported its earnings for the second quarter of 2025, with a slight beat on earnings per share expectations. The company posted a loss of $0.18 per share, compared to the anticipated loss of $0.19. No revenue figures were disclosed for this period. DiaMedica’s ongoing clinical trials and strategic initiatives were central topics during their earnings call. The company did not provide additional financial metrics or forecasts. There were no updates on any mergers or acquisitions. Analyst firms have not recently upgraded or downgraded DiaMedica’s stock. The focus remains on the company’s clinical developments and future strategic plans. These are recent developments for DiaMedica Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.